- Case report
- Open Access
- Open Peer Review
Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report
© Tazzari et al.; licensee BioMed Central. 2015
- Received: 17 July 2014
- Accepted: 27 January 2015
- Published: 14 February 2015
Clear cell sarcoma (CCS), initially named malignant melanoma of soft parts, is an aggressive soft tissue sarcoma (STS) that, due to MITF activation, shares with melanoma the expression of melanocyte differentiation antigens. CCS is poorly sensitive to chemotherapy. Multi-kinase inhibitors have been used as therapeutic agents. In the case we report here, treatment with sunitinib induced a long-lasting clinical response that was associated with an immune activation directed against Melan-A/MART-1 antigen.
A 28 years old female patient with an advanced molecularly confirmed CCS resistant to conventional chemotherapy was started in January 2012 on sunitinib, 37.5 mg/day, with evidence of radiologic and metabolic response at the primary and metastatic sites of disease. Pathologic response and loss of the Melan-A/MART-1 antigen were evidenced on residual tumor removed in April 2012. Immunological monitoring performed on patient’s blood during pharmacological treatment revealed a systemic, Melan-A/MART-1 specific immunity and a low frequency of immunosuppressive cells. Sunitinib was restarted in May 2012, with a new response, and continued for 11 months although with repeatedly interruptions due to toxicity. Disease progression and new responses were documented at each treatment interruption and restart. Sunitinib was definitively interrupted in April 2013 for disease progression.
The analysis of this case proves that antigens expressed by CCS, as for melanoma, can be immunogenic in vivo and that tumor-antigen specific T cells may exert anti-tumor activity in CCS patient. Thus, manipulation of the immune response may have therapeutic potential for this STS subtype and immunotherapy approaches, can be promising therapeutic options for these patients.
- Clear cell sarcoma
- Tumor-specific T cell
Clear cell sarcoma (CCS) is a very rare and aggressive soft tissue sarcoma (STS), usually arising from deep soft tissue or viscera , and marked by a very high metastatic risk resulting in a 5-year overall survival of about 50% [2-4]. In contrast with other STS, and similarly to melanoma, its metastatic sites include lymph nodes (LNs). CCS, initially named malignant melanoma of soft parts , are molecularly characterized in most cases by a specific translocation, t(12;22)(q13;q12), which results in fusion of the Ewing’s sarcoma gene, EWS, with the cyclic AMP (cAMP) regulated transcription factor, ATF1, a member of the cAMP-responsive element binding protein (CREB) family . The EWS-ATF1 chimeric fusion protein interacts with the MITF (melanocyte master transcription factor) promoter, thus it directly and aberrantly activates MITF expression. Consequently, CCS is characterized by the expression of the melanocytic differentiation markers HMB-45/gp100 and Melan-A/MART-1 . Overall, several immunophenotypic and molecular features are shared between CCS and malignant melanoma. Importantly, a proportion of CCS cases lack specific translocation and thus, clinical presentation as well as fluorescence in situ hybridization (FISH) analysis and reverse transcription polymerase chain reaction (RT-PCR) for the specific translocation are crucial to distinguish the two entities. Receptor tyrosine kinase expression/activation  and gene expression analysis  indicate that MITF drives the same down-stream pathways in CCS and in melanoma, and that PDGFRβ and c-Met are expressed by CCS [10,11]. Moreover, BRAF activating mutations have been occasionally detected in both EWS-ATF1 positive and negative CCS [8,12,13]. CCS is poorly sensitive to chemotherapy and anecdotal responses to regimens containing dacarbazine, vincristine, anthracycline, cyclophosphamide and to interferon-alpha-2b  have been reported. Based on the molecular features described above, multi-kinase inhibitors have been used as therapeutic agents in this STS and objective responses to sunitinib, and sorafenib treatments have been recently reported [15,16]. Here we describe a case of a 28 years old female patient with a metastatic, translocated CCS who experienced a prolonged, objective response to sunitinib malate (hereafter reported as sunitinib). We consider this case of interest as objective response to sunitinib correlated with a low frequency of immunosuppressive cells in the periphery, the presence of a systemic immunity directed against the CCS associated antigen Melan-A/MART-1 and the in vivo immune selection of post-sunitinib, MART-1 negative tumor. The analysis of this case proves that antigens expressed by CCS, as for the melanoma, can be immunogenic in vivo and that tumor-antigen specific T cells may exert anti-tumor activity in vivo.
Summary of the immune-related analysis
December 2010 (Dec-2010)
IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +
IHC: MART-1/Melan-A +; S-100 +; gp100/HMB-45 +
January 2012 (Jan-2012)
IHC: MART-1/Melan-A -; S-100 +; gp100/HMB-45 +; CD3 +; CD8 +
• Frequency of immunosuppressive cells and CD3+ T cell function (Figure 4)
May 2012/April 2013
• Presence of Melan-A/MART-1 specific CD8+ T cells (Figure 3)
We described herein the case of a CCS (HLA-A*0201) patient with advanced disease that displayed a long-lasting response to treatment with the anti-angiogenic drug sunitinib. Based on the expression and the activation status of PDGFRβ in CSC, documented by our and other groups [8,15], sunitinib likely exerts a direct inhibition of the PDGFRβ-driven pathway in the tumor cells of the patient here studied. However, along with the effect on the tumor cells, this case report documented that in this patient, objective response during sunitinib treatment was associated to traits of tumor-specific immunity. The study of this clinical case shows that antigen expresses by CCS can be immunogenic and indicates that manipulation of the immune response may have therapeutic potential in this STS subtype. As melanoma, CCS expresses the MITF-regulated genes, including genes encoding for the melanoma differentiation antigens. Thus, we look at the presence of antigen-specific response in this CCS patient. Interestingly, we observed that tumor specimen resected after treatment with sunitinib had lost the expression of MART-1 antigen. The in vivo generation of MART-1 loss variant was associated to a CD3 + CD8+ T cell infiltration and to the presence of areas of pathologic regression, thus suggesting the in vivo occurrence of MART1-specific response. This immune contexture at the tumor site was paralleled by the finding that functionally active anti-MART-1 T cells were detectable in the blood of this patients collected during sunitinib treatment. To our knowledge this is the first report documenting the in vivo immunogenicity of CCS tumor. The immune response in the CSC patient studied in this report was directed toward Melan-A/MART-1. No specific immunity directed against the less immunogenic differentiation antigen gp100 was developed and, as expected, reactivity for HMB-45/gp100 was maintained in post-sunitinib surgical specimen. These findings are in line with the observation that Melan-A/MART-1/HLA-A*0201 restricted peptide behaves as immune-dominant epitope in melanoma patients and a high proportion (about 70%) of advanced stage III-IV melanoma patients display a natural anti-Melan-A/MART-1 immunity . In the peripheral blood of this patient, we observed that sunitinib treatment sustained a down-modulation in the frequency of immune suppressive cells, Tregs and mMDSCs, and a parallel activation of T cell functions evaluated by the capacity of CD3+ T cells to release Th1 cytokines in response to a polyclonal stimulation. The immunomodulatory function of sunitinib has been clearly documented in other human tumors and we confirmed this activity in the setting of CCS [23,24]. However, our observations also suggest that the release in the immune suppression induced by sunitinib may have unleashed anti-tumor immunity in this CCS patient. Indeed, this hypothesis is in agreement with the observation that, in melanoma patients, antigen-specific responses are prevented by the presence of high frequency of circulating mMDSCs . By contrast a decrease of their number favors the clinical response in patients treated with immunotherapy .
In conclusion, this case shed light on immune-similarities between CCS and melanoma, and indicates that manipulation of the immune response in this STS subtype likely evokes antigen-specific response. In addition to T cells specific for MITF-regulated antigens, anti-tumor immunity may potentially include also T cells recognizing unique, mutation-specific determinants. As previously shown by in vitro immunological assays , the chimeric protein encoded by the specific chromosome translocation of CCS is certainly a source for these type of antigens and it is well known that immune response directed to mutated antigens plays a crucial role in determining tumor rejection and clinical response in cancer patients under immunotherapy regimens [28,29]. Although generalized conclusion cannot be depicted from a single case, these findings suggest that immunotherapy approaches, which include tumor-specific vaccine and antibodies directed to immunological checkpoints, such as ipilimumab (anti-CTLA4) or nivolumab (anti-PD1), may offer, alone or in association with targeted-therapies, a new therapeutic option for advanced CCS patients, for which no successful therapies are currently available.
PBMCs and cell lines
PBMCs were obtained by Ficoll density gradient centrifugation followed by cryopreservation. 501mel cell line was generated as previously described , 624.38mel and 624.28mel were cloned as previously described . A375mel and the lymphoblastoid cell line T2 were obtained from the American Type Cell Culture (ATCC). All these cell lines were cultured in RPMI 1640 (Lonza) supplemented with 10% FCS (Lonza), Hepes and antibiotics. For tumor cell line immuno-phenotyping, the FITC–labeled BB7.2 monoclonal antibody (BD Bioscences, San Diego, CA) was used.
Immunohistochemical analysis of antigen expression in tumor biopsies
5-μm thick formalin-fixed, paraffin-embedded tissue sections were processed for IHC staining. The monoclonal antibodies used were directed against the following antigens: anti-S100, anti-Melan-A/MART-1, anti-HMB-45/gp100, anti-CD8 (DAKO) and anti-CD3 (Novocastra).
Lymphocyte stimulation and Enzyme-Linked ImmunoSpot (ELISpot) assay
PBMCs isolated from the patient were thawed and cultured in the presence of the HLA2-A*0201 restricted-modified peptides (Melan-A/MART-1[27L] or gp100[210M]) (2 μmol/L) plus 60 IU/mL IL-2 (Proleukin). The cells were tested every 10 to 14 days by flow cytometry analysis for the enrichment of CD8+pentamer+ T cells. To assess their reactivity against tumor cells, IFN-γ release was determined by ELISpot assay (Mabtech) in the presence of MART1 (modified or native)-pulsed (2 μmol/L) lymphoblastoid T2 cell line or HLA-A*0201+/− (MART+/−) melanoma cell lines. HLA class I-blocking experiments required preincubation of target cells with the W6/32 mAb.
Flow cytometry analysis of antigen specific T cells and immunosuppressive cells
Phenotypic characterization of T cell cultures was done by the multiparametric flow cytometry analysis using the following mAbs: anti-CD8-Krome Orange (Beckman Coulter, Brea, CA), anti-CD4-APC (BD Bioscences), the HLA-A*0201 multimers were provided by Proimmune Ltd. Tregs and MDSCs frequencies were determined by multi-colour immunofluorescence staining of thawed PBMCs, excluding dead cells using the LIVE-DEAD® Fixable Violet Dead Cell Stain Kit (Life Technologies, Carlsbad, CA). For surface staining, after treatment with FcR Blocking Reagent (Miltenyi, Bergisch-Gladbach, Germany), cells were incubated with the following antibodies for 30 minutes at 4°C :APCH7-conjugated anti-CD4, PE-Cy7-conjugated anti-CD25 (for detecting Treg); APCH7 conjugated anti-CD14, PE-Cy7-conjugated anti-CD11b, PE-conjugated anti-HLADR (for detecting mMDSC). All antibodies were from BD Bioscences except PE-Cy7-conjugated anti-CD11b (from Beckman Coulter). For Treg analysis, intracellular staining with APC-conjugated anti-Foxp3 (eBioscience) or the proper isotype control (rat IgG2a) was performed. Lymphocytes activated overnight with anti-CD3/CD28 beads (DynaBeads® CD3/CD28 T cell Expander, Invitrogen Dynal AS, Oslo, Norway) in the presence of 1 μl/ml Golgi Plug (BD Biosciences) were stained for the cell surface marker CD3. The cells were then washed, fixed and permeabilized with Cytofix/Cytoperm buffer (BD Biosciences) and stained with a 488-labelled anti-IFN-γ (BioLegend), PE-labelled anti-IL-2 (BD Biosciences). Data acquisition was performed using a Gallios™ (Beckman Coulter) flow cytometer, and the Kaluza® software (Tree Star Inc, Ashland, OR) was used for data analysis.
Written informed consent was obtained from the patient. A copy of the written consent is available for review by the Editor of this journal.
The authors thank Dr. Paola Frati and Mrs. Felicetta Giardino (Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) for their precious help in the clinical data management. We are grateful to Dr. Valeria Beretta (Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) for expert technical help. This study was supported by AIRC (Associazione Italiana Ricerca sul Cancro) (IG grants: CC (10615), SP (10300)). MT is supported by a fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro).
- Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983;7(5):405–13.View ArticlePubMedGoogle Scholar
- Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB. Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer. 1999;86(6):969–75.View ArticlePubMedGoogle Scholar
- Eckardt JJ, Pritchard DJ, Soule EH. Clear cell sarcoma. A clinicopathologic study of 27 cases. Cancer. 1983;52(8):1482–8.View ArticlePubMedGoogle Scholar
- Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007;109(1):109–16.View ArticlePubMedGoogle Scholar
- Weis S, Goldblum J. Malignant Tumors of Uncertain Type. St-Louis, MO: Mosby: Enzinger and Weiss’s Soft Tissue Tumors; 2001.Google Scholar
- Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4(4):341–5.View ArticlePubMedGoogle Scholar
- Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell. 2006;9(6):473–84.View ArticlePubMedGoogle Scholar
- Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, et al. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Genes Chromosomes Cancer. 2012;51(2):111–26.View ArticlePubMedGoogle Scholar
- Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol. 2003;21(9):1775–81.View ArticlePubMedGoogle Scholar
- Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010;70(2):639–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67(3):919–29.View ArticlePubMedGoogle Scholar
- Hocar O, Le Cesne A, Berissi S, Terrier P, Bonvalot S, Vanel D, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012;2012:984096.PubMedPubMed CentralGoogle Scholar
- Park BM, Jin SA, Choi YD, Shin SH, Jung ST, Lee JB, et al. Two cases of clear cell sarcoma with different clinical and genetic features: cutaneous type with BRAF mutation and subcutaneous type with KIT mutation. Br J Dermatol. 2013;169(6):1346–52.View ArticlePubMedGoogle Scholar
- Steger W, Steger GG, Wrba F, Mader R, Schlappack O, Dittrich C, et al. Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. Eur J Cancer. 1991;27(3):254–6. PubMed PMID: 1827307.View ArticlePubMedGoogle Scholar
- Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010;21(5):1130–1.View ArticlePubMedGoogle Scholar
- Mir O, Boudou-Rouquette P, Larousserie F, Babinet A, Dumaine V, Anract P, et al. Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol. 2012;23(3):807–9.View ArticlePubMedGoogle Scholar
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.View ArticlePubMedGoogle Scholar
- Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546–53.View ArticlePubMedGoogle Scholar
- Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70(11):4335–45. doi:10.1158/0008-5472.CAN-09-3767. Epub 2010 May.View ArticlePubMedGoogle Scholar
- Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43. doi:10.1053/j.gastro.2008.03.020. Epub 2008 Mar 21. Erratumin: Gastroenterology. 2011 Aug;141(2):779. PubMed PMID: 18485901.View ArticlePubMedGoogle Scholar
- Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamideassociates with longer patient survival. Nat Med. 2012;18(8):1254–61. doi:10.1038/nm.2883. Epub 2012 Jul 29. PubMed PMID: 22842478.View ArticlePubMedGoogle Scholar
- Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002;188:81–96.View ArticlePubMedGoogle Scholar
- Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer. 2011;129(9):2158–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148–57.View ArticlePubMedGoogle Scholar
- Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells. Clin Cancer Res. 2014;20(6):1601–9.View ArticlePubMedGoogle Scholar
- Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. doi: 10.1056/NEJMoa1112824. PubMed PMID: 22397654; PubMedCentral PMCID: PMC3345206.View ArticlePubMedPubMed CentralGoogle Scholar
- Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001;61(18):6868–75.PubMedGoogle Scholar
- Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–5. doi:10.1126/science.1251102. PubMed PMID: 24812403.View ArticlePubMedGoogle Scholar
- Van Rooij N, Van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42. doi:10.1200/JCO.2012.47.7521. Epub 2013 Sep 16. PubMed PMID: 24043743; PubMed Central PMCID: PMC3836220.View ArticlePubMedGoogle Scholar
- Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91(9):3515–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995;55(14):3149–57.PubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.